Marktanalyse - Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2012
GlobalData
5 / 2012
86 Seiten
| Typ: | Marktanalyse |
| Sprache: | Englisch |
| Regionen: | Europa, Asien / Pazifik, Mittlerer Osten / Afrika, Nordamerika / USA, Australien, Mittel- / Südamerika |
| Verfügbarkeit: | verfügbar |
Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2012
Summary
GlobalData's 'Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2012” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions recorded in the pharmaceutical and healthcare industry in Q1 2012. The report presents detailed comparative data on the number of deals and their value in the last five quarters, categorized into deal types, segments, and geographies. The report also provides information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database and primary and secondary research.
Scope
- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include — North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to buy
- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Press Release:
Values Of Pharmaceutical & Healthcare Deals Were Down 34% In Q1 2012.
GlobalData's 'Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2012” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions registered in the pharmaceutical and healthcare industry in Q1 2012. The report presents detailed comparative data on the number of deals and their value in the past five quarters subdivided into deal types, segments, and geographies. The report also offers information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database and through primary and secondary research.
Pharmaceutical And Healthcare Industry Reported A Decrease In M&A Activity In Q1 2012
M&A deals, including asset purchases, reported a decrease in the number of deals and deal values in Q1 2012. The segment recorded 214 deals worth $15.4 billion, as compared to 254 deals worth $26.1 billion in Q4 2011. On a year-on-year basis, the deal activity decreased in Q1 2012, when compared to 321 deals worth $28.1 billion in Q1 2011.
The oncology therapeutics market accounted for the majority of M&As during Q1 2012. The market recorded 17 deals worth $5.3 billion in Q4 2011. Central nervous system therapeutics market was in second place with 15 deals worth $1.8 billion.
Some of the high value deals in Q1 2012 include, Dainippon Sumitomo Pharma announcing to acquire Boston Biomedical Inc. (BBI), a biotechnology company, for approximately $2.6 billion; Bristol-Myers Squibb’s acquisition of Inhibitex, Inc., a biotechnology company, for a purchase consideration of approximately $2.5 billion and Amgen completing the tender offer to acquire all the outstanding shares of Micromet, Inc., a biotechnology company, for a cash consideration of $1.16 billion.
According to Khaleeq Zakariya, analyst at GlobalData, 'Global merger and acquisition (M&A) activity in the pharmaceutical and healthcare industry witnessed a slow start in the first quarter of 2012, compared with the last three quarters of 2011, and was low compared to the same period in 2011. This suggests that economic uncertainty in the global market remains. North America has recorded a steep decline in both deal values and deal volume between the fourth quarter of 2011 and the first quarter of 2012 and Europe also witnessed a decrease in the number of deals and deal values in first quarter of 2012 as compared to fourth quarter of 2011. All other world markets, including Asia-Pacific saw the number of deals rise in the first quarter of 2012 over the fourth quarter of 2011 but saw the deal values decrease over that same period.”
Partnership Deals Decline Marginally In Q1 2012
Partnership deals reported a decline in the number of deals and deal values in Q1 2012 with 175 deals worth $4.3 billion, as compared to 179 deals worth $4.8 billion in Q4 2011. On a year-on-year basis, the number of deals and deal values decreased in Q1 2012, when compared to 268 deals worth $6.6 billion in Q1 2011. Out of 175 deals reported in Q1 2012, 109 were co-development deals, 31 were co-marketing deals, 23 were joint venture deals and 12 were related to other category.
Abbott Laboratories collaboration agreement worth $1.2 billion with Galapagos, to develop and commercialize GLPG0634, an oral JAK1 inhibitor in Phase II development with the potential to treat multiple autoimmune diseases, was one the major partnership transaction reported in Q1 2012.
Number Of Licensing Agreement Increase In Q1 2012
Licensing agreements recorded an increase in the number of deals with 134 deals in Q1 2012, as compared to 115 deals in Q4 2011. However, dollar value of licensing deals declined reporting $2.8 billion in Q1 2012, as compared 4.3 billion in Q4 2011. On a year-on-year basis, the number of deals and deal values decreased in Q1 2012, when compared with 162 deals worth $5.5 billion in Q1 2011.
In licensing by phase, products in Phase III recorded 89 deals, accounting for 23% of the total deals in last five quarters. In second place, products in Phase II accounted for 21% of the deals. In deal values, Phase III products accounted for 29% of the deal value.
Xenon Pharmaceuticals’ licensing agreement with Genentech to discover and develop compounds and companion diagnostics for the potential treatment of pain, ThromboGenics’ licensing agreement with Alcon for the commercialization of Ocriplasmin outside the US for the treatment of symptomatic vitreomacular adhesion (VMA) and Enanta Pharmaceuticals’ licensing agreement with Novartis for EDP-239, were some of the notable licensing deals in Q1 2012.
VC Capital Investors Decrease Their Investments In Q1 2012
The pharmaceutical and healthcare industry recorded a decrease in deal values in Q1 2012 with $1.4 billion as compared to $1.8 billion in Q4 2011. However, the number of deals increased to 235 from 228 in Q4 2011. On a year-on-year basis, the number of deals increased and deal values decreased in Q1 2012, when compared to 165 deals worth $1.5 billion in Q1 2011. Out of 235 deals recorded in Q1 2012, 141 were start-up stage financing deals worth $861.8m, 59 were growth/ expansion stage financing deals worth $350.9m, 18 seed stage financing deals worth $14.9m and 17 were later stage financing deals worth $201m.
According to Khaleeq Zakariya, analyst at GlobalData, 'The global pharmaceutical and healthcare industry recorded an increase in number of venture capital deals and a decrease in deal values in first quarter of 2012 as compared to the fourth quarter of 2011, suggesting an on-going sense of caution among venture capitalists. However, start-up stage financing peaked in first quarter of 2012. Globally, the oncology therapeutics market recorded the highest number of venture capital deals, followed by the central nervous system and immunology therapeutics market during the first quarter of 2011 to first quarter of 2012”.
Number Of Deals Increase In North America In Q1 2012
North America recorded an increase in the number of deals and a sharp decrease in deal values in Q1 2012. The region registered 702 deals worth $34.7 billion in Q1 2012, as compared to 693 deals worth $61.9 billion in Q4 2011. On a year-on-year basis, the number of deals and deal values decreased in Q1 2012, when compared to 764 deals worth $44.8 billion in Q1 2011.
Europe recorded a decrease in the number of deals and an increase in deal values in Q1 2012 with 233 deals worth $12.7 billion, as compared to 244 deals worth $12 billion in Q4 2011. On a year-on-year basis, the number of deals and the deal values decreased in Q1 2012, when compared to 339 deals worth $33.4 billion in Q1 2011.
Asia Pacific recorded a decline in the number of deals and deal values in Q1 2012. The region reported 204 deals worth $8.2 billion in Q1 2012, as compared to 213 deals worth $11.7 billion in Q4 2011. On a year-on-year basis, the number of deals and the deal values decreased in Q1 2012, when compared to 251 deals worth $15.2 billion in Q1 2011.
Summary
GlobalData's 'Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2012” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions recorded in the pharmaceutical and healthcare industry in Q1 2012. The report presents detailed comparative data on the number of deals and their value in the last five quarters, categorized into deal types, segments, and geographies. The report also provides information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database and primary and secondary research.
Scope
- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include — North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to buy
- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Press Release:
Values Of Pharmaceutical & Healthcare Deals Were Down 34% In Q1 2012.
GlobalData's 'Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2012” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions registered in the pharmaceutical and healthcare industry in Q1 2012. The report presents detailed comparative data on the number of deals and their value in the past five quarters subdivided into deal types, segments, and geographies. The report also offers information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database and through primary and secondary research.
Pharmaceutical And Healthcare Industry Reported A Decrease In M&A Activity In Q1 2012
M&A deals, including asset purchases, reported a decrease in the number of deals and deal values in Q1 2012. The segment recorded 214 deals worth $15.4 billion, as compared to 254 deals worth $26.1 billion in Q4 2011. On a year-on-year basis, the deal activity decreased in Q1 2012, when compared to 321 deals worth $28.1 billion in Q1 2011.
The oncology therapeutics market accounted for the majority of M&As during Q1 2012. The market recorded 17 deals worth $5.3 billion in Q4 2011. Central nervous system therapeutics market was in second place with 15 deals worth $1.8 billion.
Some of the high value deals in Q1 2012 include, Dainippon Sumitomo Pharma announcing to acquire Boston Biomedical Inc. (BBI), a biotechnology company, for approximately $2.6 billion; Bristol-Myers Squibb’s acquisition of Inhibitex, Inc., a biotechnology company, for a purchase consideration of approximately $2.5 billion and Amgen completing the tender offer to acquire all the outstanding shares of Micromet, Inc., a biotechnology company, for a cash consideration of $1.16 billion.
According to Khaleeq Zakariya, analyst at GlobalData, 'Global merger and acquisition (M&A) activity in the pharmaceutical and healthcare industry witnessed a slow start in the first quarter of 2012, compared with the last three quarters of 2011, and was low compared to the same period in 2011. This suggests that economic uncertainty in the global market remains. North America has recorded a steep decline in both deal values and deal volume between the fourth quarter of 2011 and the first quarter of 2012 and Europe also witnessed a decrease in the number of deals and deal values in first quarter of 2012 as compared to fourth quarter of 2011. All other world markets, including Asia-Pacific saw the number of deals rise in the first quarter of 2012 over the fourth quarter of 2011 but saw the deal values decrease over that same period.”
Partnership Deals Decline Marginally In Q1 2012
Partnership deals reported a decline in the number of deals and deal values in Q1 2012 with 175 deals worth $4.3 billion, as compared to 179 deals worth $4.8 billion in Q4 2011. On a year-on-year basis, the number of deals and deal values decreased in Q1 2012, when compared to 268 deals worth $6.6 billion in Q1 2011. Out of 175 deals reported in Q1 2012, 109 were co-development deals, 31 were co-marketing deals, 23 were joint venture deals and 12 were related to other category.
Abbott Laboratories collaboration agreement worth $1.2 billion with Galapagos, to develop and commercialize GLPG0634, an oral JAK1 inhibitor in Phase II development with the potential to treat multiple autoimmune diseases, was one the major partnership transaction reported in Q1 2012.
Number Of Licensing Agreement Increase In Q1 2012
Licensing agreements recorded an increase in the number of deals with 134 deals in Q1 2012, as compared to 115 deals in Q4 2011. However, dollar value of licensing deals declined reporting $2.8 billion in Q1 2012, as compared 4.3 billion in Q4 2011. On a year-on-year basis, the number of deals and deal values decreased in Q1 2012, when compared with 162 deals worth $5.5 billion in Q1 2011.
In licensing by phase, products in Phase III recorded 89 deals, accounting for 23% of the total deals in last five quarters. In second place, products in Phase II accounted for 21% of the deals. In deal values, Phase III products accounted for 29% of the deal value.
Xenon Pharmaceuticals’ licensing agreement with Genentech to discover and develop compounds and companion diagnostics for the potential treatment of pain, ThromboGenics’ licensing agreement with Alcon for the commercialization of Ocriplasmin outside the US for the treatment of symptomatic vitreomacular adhesion (VMA) and Enanta Pharmaceuticals’ licensing agreement with Novartis for EDP-239, were some of the notable licensing deals in Q1 2012.
VC Capital Investors Decrease Their Investments In Q1 2012
The pharmaceutical and healthcare industry recorded a decrease in deal values in Q1 2012 with $1.4 billion as compared to $1.8 billion in Q4 2011. However, the number of deals increased to 235 from 228 in Q4 2011. On a year-on-year basis, the number of deals increased and deal values decreased in Q1 2012, when compared to 165 deals worth $1.5 billion in Q1 2011. Out of 235 deals recorded in Q1 2012, 141 were start-up stage financing deals worth $861.8m, 59 were growth/ expansion stage financing deals worth $350.9m, 18 seed stage financing deals worth $14.9m and 17 were later stage financing deals worth $201m.
According to Khaleeq Zakariya, analyst at GlobalData, 'The global pharmaceutical and healthcare industry recorded an increase in number of venture capital deals and a decrease in deal values in first quarter of 2012 as compared to the fourth quarter of 2011, suggesting an on-going sense of caution among venture capitalists. However, start-up stage financing peaked in first quarter of 2012. Globally, the oncology therapeutics market recorded the highest number of venture capital deals, followed by the central nervous system and immunology therapeutics market during the first quarter of 2011 to first quarter of 2012”.
Number Of Deals Increase In North America In Q1 2012
North America recorded an increase in the number of deals and a sharp decrease in deal values in Q1 2012. The region registered 702 deals worth $34.7 billion in Q1 2012, as compared to 693 deals worth $61.9 billion in Q4 2011. On a year-on-year basis, the number of deals and deal values decreased in Q1 2012, when compared to 764 deals worth $44.8 billion in Q1 2011.
Europe recorded a decrease in the number of deals and an increase in deal values in Q1 2012 with 233 deals worth $12.7 billion, as compared to 244 deals worth $12 billion in Q4 2011. On a year-on-year basis, the number of deals and the deal values decreased in Q1 2012, when compared to 339 deals worth $33.4 billion in Q1 2011.
Asia Pacific recorded a decline in the number of deals and deal values in Q1 2012. The region reported 204 deals worth $8.2 billion in Q1 2012, as compared to 213 deals worth $11.7 billion in Q4 2011. On a year-on-year basis, the number of deals and the deal values decreased in Q1 2012, when compared to 251 deals worth $15.2 billion in Q1 2011.
1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 6
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q1 2012 8
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q1 2012 8
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals and Deal Values, Q1 2012 10
2.3 Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2012 11
2.3.1 Dainippon Sumitomo Pharma Completes Acquisition Of Boston Biomedical 11
2.3.2 Bristol-Myers Squibb Completes Acquisition Of Inhibitex, Hepatitis C Drug Developer, For $2.5 Billion 11
2.3.3 Amgen Completes Tender Offer To Acquire Micromet For $1.16 Billion 12
2.3.4 Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 12
2.3.5 Health Care REIT And Chartwell Seniors Housing To Acquire Portfolio Of Seniors Housing Care Communities For $925 Million 12
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 13
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q1 2012 13
3.1.1 Top M&A Deals in Q1 2012 14
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q1 2011 - Q1 2012 15
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q1 2012 16
3.2.1 Top Initial Public Offerings in Q1 2012 17
3.2.2 Top Secondary Offerings in Q1 2012 17
3.2.3 Top PIPE Deals in Q1 2012 17
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q1 2011-Q1 2012 18
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q1 2011 - Q1 2012 19
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q1 2012 20
3.3.1 Top Venture Financing Deals in Q1 2012 21
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2012 22
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q1 2011 - Q1 2012 23
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 24
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 25
3.3.6 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q1 2012 26
3.3.7 Top Private Equity Deals in Q1 2012 27
3.3.8 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q1 2011 - Q1 2012 28
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2012 29
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2012 29
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q1 2011 - Q1 2012 30
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2012 31
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q1 2012 32
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2012 32
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q1 2012 33
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2011 - Q1 2012 34
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 35
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2011 - Q1 2012 36
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q1 2012 37
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q1 2012 37
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2011 - Q1 2012 38
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q1 2012 39
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q1 2012 39
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q1 2012 40
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q1 2011 - Q1 2012 41
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q1 2011 - Q1 2012 42
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2011 - Q1 2012 43
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q1 2011 - Q1 2012 44
6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 45
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q1 2011 - Q1 2012 45
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q1 2011 - Q1 2012 46
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2011 - Q1 2012 47
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q1 2011 - Q1 2012 48
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q1 2011 - Q1 2012 49
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q1 2011 - Q1 2012 50
6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2011 - Q1 2012 51
7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 52
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q1 2012 52
7.1.1 Oncology - Deals of the Quarter 53
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q1 2012 54
7.2.1 Central Nervous System - Deals of the Quarter 55
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q1 2012 56
7.3.1 Infectious Disease - Deals of the Quarter 57
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q1 2012 58
7.4.1 Immunology - Deals of the Quarter 59
7.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q1 2012 60
7.5.1 Cardiovascular - Deals of the Quarter 61
7.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q1 2012 62
7.6.1 Metabolic Disorders - Deals of the Quarter 63
7.7 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q1 2012 64
7.7.1 Respiratory - Deals of the Quarter 65
7.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q1 2012 66
7.8.1 Dermatology - Deals of the Quarter 67
7.9 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q1 2012 68
7.9.1 Gastrointestinal - Deals of the Quarter 69
7.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q1 2012 70
7.10.1 Ophthalmology - Deals of the Quarter 71
8 Deal Summary by Geography 72
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q1 2012 72
8.1.1 North America - Deals of the Quarter 73
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q1 2012 74
8.2.1 Europe - Deals of the Quarter 75
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q1 2012 76
8.3.1 Asia-Pacific - Deals of the Quarter 77
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q1 2012 78
8.4.1 Rest of the World - Deals of the Quarter 79
9 Pharmaceuticals & Healthcare, Global, Top Advisors 80
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 80
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 81
10 Appendix 82
11 Further Information 85
11.1 Methodology 85
11.2 About GlobalData 85
11.3 Contact Us 86
11.4 Disclosure information 86
11.5 Disclaimer 86
1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q1 2011 - Q1 2012 9
Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q1 2012 10
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2012 11
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 13
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q1 2012 14
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q1 2011 - Q1 2012 15
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2011 - Q1 2012 16
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q1 2012 17
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q1 2012 17
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q1 2012 17
Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q1 2011-Q1 2012 18
Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2011 - Q1 2012 19
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 20
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q1 2012 21
Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q1 2012 22
Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2011 - Q1 2012 23
Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q2 2011 - Q1 2012 24
Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q2 2011 - Q1 2012 25
Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 26
Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q1 2012 27
Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2011 - Q1 2012 28
Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 29
Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 30
Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2011 - Q1 2012 31
Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2012 32
Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2012 32
Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q1 2012 33
Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2011 - Q1 2012 34
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2011 - Q1 2012 35
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2011 - Q1 2012 36
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 37
Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2011 - Q1 2012 38
Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q1 2012 39
Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q1 2012 39
Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q1 2012 40
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 41
Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q1 2011 - Q1 2012 42
Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2011 - Q1 2012 43
Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2011 - Q1 2012 44
Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q1 2011 - Q1 2012 45
Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q1 2011 - Q1 2012 46
Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2011 - Q1 2012 47
Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q1 2011 - Q1 2012 48
Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2009 - Q1 2012 49
Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q1 2011 - Q1 2012 50
Table 46: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2011 - Q1 2012 51
Table 47: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 53
Table 48: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 55
Table 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 56
Table 50: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 59
Table 51: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 60
Table 52: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 62
Table 53: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 65
Table 54: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 66
Table 55: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 68
Table 56: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 70
Table 57: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 73
Table 58: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 75
Table 59: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 77
Table 60: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 79
Table 61: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q2 2011 - Q1 2012 80
Table 62: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 81
Table 63: Pharmaceuticals & Healthcare, Deals’ Key Financials, Global Acquisition Deals, Q1 2011-Q1 2012 82
1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q1 2011 - Q1 2012 8
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%) and Deal Values (%), Q1 2012 10
Figure 3: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q1 2011 - Q1 2012 13
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q1 2011 - Q1 2012 15
Figure 5: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 16
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q1 2011 - Q1 2012 19
Figure 7: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 20
Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%) and Deal Values (%), Q1 2012 22
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2011 - Q1 2012 23
Figure 10: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q2 2011 - Q1 2012 24
Figure 11: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 26
Figure 12: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2011 - Q1 2012 28
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 29
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 30
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2011 - Q1 2012 31
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2011 - Q1 2012 34
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2011 - Q1 2012 35
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2011 - Q1 2012 36
Figure 19: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 37
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2011 - Q1 2012 38
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 41
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2011 - Q1 2012 42
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 43
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2011 - Q1 2012 44
Figure 25: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q1 2011 - Q1 2012 45
Figure 26: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q1 2011 - Q1 2012 46
Figure 27: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2011 - Q1 2012 47
Figure 28: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q1 2011 - Q1 2012 48
Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q1 2011 - Q1 2012 49
Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q1 2011 - Q1 2012 50
Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2011 - Q1 2012 51
Figure 32: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 52
Figure 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 54
Figure 34: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 56
Figure 35: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 58
Figure 36: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 60
Figure 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 62
Figure 38: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 64
Figure 39: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 66
Figure 40: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 68
Figure 41: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 70
Figure 42: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 72
Figure 43: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 74
Figure 44: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 76
Figure 45: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 78
Figure 46: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q2 2011 - Q1 2012 80
Figure 47: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q2 2011 - Q1 2012 81
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 6
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q1 2012 8
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q1 2012 8
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals and Deal Values, Q1 2012 10
2.3 Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2012 11
2.3.1 Dainippon Sumitomo Pharma Completes Acquisition Of Boston Biomedical 11
2.3.2 Bristol-Myers Squibb Completes Acquisition Of Inhibitex, Hepatitis C Drug Developer, For $2.5 Billion 11
2.3.3 Amgen Completes Tender Offer To Acquire Micromet For $1.16 Billion 12
2.3.4 Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 12
2.3.5 Health Care REIT And Chartwell Seniors Housing To Acquire Portfolio Of Seniors Housing Care Communities For $925 Million 12
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 13
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q1 2012 13
3.1.1 Top M&A Deals in Q1 2012 14
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q1 2011 - Q1 2012 15
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q1 2012 16
3.2.1 Top Initial Public Offerings in Q1 2012 17
3.2.2 Top Secondary Offerings in Q1 2012 17
3.2.3 Top PIPE Deals in Q1 2012 17
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q1 2011-Q1 2012 18
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q1 2011 - Q1 2012 19
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q1 2012 20
3.3.1 Top Venture Financing Deals in Q1 2012 21
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2012 22
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q1 2011 - Q1 2012 23
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 24
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 25
3.3.6 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q1 2012 26
3.3.7 Top Private Equity Deals in Q1 2012 27
3.3.8 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q1 2011 - Q1 2012 28
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2012 29
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2012 29
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q1 2011 - Q1 2012 30
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2012 31
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q1 2012 32
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2012 32
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q1 2012 33
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2011 - Q1 2012 34
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 35
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2011 - Q1 2012 36
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q1 2012 37
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q1 2012 37
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2011 - Q1 2012 38
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q1 2012 39
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q1 2012 39
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q1 2012 40
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q1 2011 - Q1 2012 41
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q1 2011 - Q1 2012 42
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2011 - Q1 2012 43
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q1 2011 - Q1 2012 44
6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 45
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q1 2011 - Q1 2012 45
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q1 2011 - Q1 2012 46
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2011 - Q1 2012 47
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q1 2011 - Q1 2012 48
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q1 2011 - Q1 2012 49
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q1 2011 - Q1 2012 50
6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2011 - Q1 2012 51
7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 52
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q1 2012 52
7.1.1 Oncology - Deals of the Quarter 53
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q1 2012 54
7.2.1 Central Nervous System - Deals of the Quarter 55
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q1 2012 56
7.3.1 Infectious Disease - Deals of the Quarter 57
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q1 2012 58
7.4.1 Immunology - Deals of the Quarter 59
7.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q1 2012 60
7.5.1 Cardiovascular - Deals of the Quarter 61
7.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q1 2012 62
7.6.1 Metabolic Disorders - Deals of the Quarter 63
7.7 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q1 2012 64
7.7.1 Respiratory - Deals of the Quarter 65
7.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q1 2012 66
7.8.1 Dermatology - Deals of the Quarter 67
7.9 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q1 2012 68
7.9.1 Gastrointestinal - Deals of the Quarter 69
7.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q1 2012 70
7.10.1 Ophthalmology - Deals of the Quarter 71
8 Deal Summary by Geography 72
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q1 2012 72
8.1.1 North America - Deals of the Quarter 73
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q1 2012 74
8.2.1 Europe - Deals of the Quarter 75
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q1 2012 76
8.3.1 Asia-Pacific - Deals of the Quarter 77
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q1 2012 78
8.4.1 Rest of the World - Deals of the Quarter 79
9 Pharmaceuticals & Healthcare, Global, Top Advisors 80
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 80
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 81
10 Appendix 82
11 Further Information 85
11.1 Methodology 85
11.2 About GlobalData 85
11.3 Contact Us 86
11.4 Disclosure information 86
11.5 Disclaimer 86
1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q1 2011 - Q1 2012 9
Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q1 2012 10
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2012 11
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 13
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q1 2012 14
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q1 2011 - Q1 2012 15
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2011 - Q1 2012 16
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q1 2012 17
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q1 2012 17
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q1 2012 17
Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q1 2011-Q1 2012 18
Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2011 - Q1 2012 19
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 20
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q1 2012 21
Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q1 2012 22
Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2011 - Q1 2012 23
Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q2 2011 - Q1 2012 24
Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q2 2011 - Q1 2012 25
Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 26
Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q1 2012 27
Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2011 - Q1 2012 28
Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 29
Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 30
Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2011 - Q1 2012 31
Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2012 32
Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2012 32
Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q1 2012 33
Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2011 - Q1 2012 34
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2011 - Q1 2012 35
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2011 - Q1 2012 36
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 37
Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2011 - Q1 2012 38
Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q1 2012 39
Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q1 2012 39
Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q1 2012 40
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 41
Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q1 2011 - Q1 2012 42
Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2011 - Q1 2012 43
Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2011 - Q1 2012 44
Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q1 2011 - Q1 2012 45
Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q1 2011 - Q1 2012 46
Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2011 - Q1 2012 47
Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q1 2011 - Q1 2012 48
Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2009 - Q1 2012 49
Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q1 2011 - Q1 2012 50
Table 46: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2011 - Q1 2012 51
Table 47: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 53
Table 48: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 55
Table 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 56
Table 50: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 59
Table 51: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 60
Table 52: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 62
Table 53: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 65
Table 54: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 66
Table 55: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 68
Table 56: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 70
Table 57: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 73
Table 58: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 75
Table 59: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 77
Table 60: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 79
Table 61: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q2 2011 - Q1 2012 80
Table 62: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 81
Table 63: Pharmaceuticals & Healthcare, Deals’ Key Financials, Global Acquisition Deals, Q1 2011-Q1 2012 82
1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q1 2011 - Q1 2012 8
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%) and Deal Values (%), Q1 2012 10
Figure 3: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q1 2011 - Q1 2012 13
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q1 2011 - Q1 2012 15
Figure 5: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 16
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q1 2011 - Q1 2012 19
Figure 7: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 20
Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%) and Deal Values (%), Q1 2012 22
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2011 - Q1 2012 23
Figure 10: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q2 2011 - Q1 2012 24
Figure 11: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 26
Figure 12: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2011 - Q1 2012 28
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 29
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 30
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2011 - Q1 2012 31
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2011 - Q1 2012 34
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2011 - Q1 2012 35
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2011 - Q1 2012 36
Figure 19: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 37
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2011 - Q1 2012 38
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 41
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2011 - Q1 2012 42
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 43
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2011 - Q1 2012 44
Figure 25: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q1 2011 - Q1 2012 45
Figure 26: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q1 2011 - Q1 2012 46
Figure 27: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2011 - Q1 2012 47
Figure 28: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q1 2011 - Q1 2012 48
Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q1 2011 - Q1 2012 49
Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q1 2011 - Q1 2012 50
Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2011 - Q1 2012 51
Figure 32: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 52
Figure 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 54
Figure 34: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 56
Figure 35: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 58
Figure 36: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 60
Figure 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 62
Figure 38: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 64
Figure 39: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 66
Figure 40: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 68
Figure 41: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 70
Figure 42: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 72
Figure 43: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 74
Figure 44: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 76
Figure 45: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q1 2011 - Q1 2012 78
Figure 46: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q2 2011 - Q1 2012 80
Figure 47: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q2 2011 - Q1 2012 81
- ICT Spend Predictions in Large Brazilian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Large Canadian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Large French Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Large German Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Large Mexican Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Large UK Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Large US Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Medium-sized Brazilian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Medium-sized Canadian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Medium-sized French Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Medium-sized German Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Medium-sized Mexican Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Medium-sized UK Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Medium-sized US Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Small Brazilian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Small Canadian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Small French Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Small German Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Small Mexican Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Small UK Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
*Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.
Hinweise: **The report can be shared by users within one office (one geographical location)
***Across Geographical locations (by the purchasing company only)
Für Sie protokollierte Studien / Marktanalysen:
zuletzt angesehene Studien:
Seite drucken
Seite empfehlen
Home | Werbung | Über marktforschung.de | AGB | Impressum | Sitemap | Suche © 2006 bis 2013 Alle Rechte bei marktforschung.de - Studie - Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2012 - Marktdaten / Marktanalysen bei marktforschung.de
